Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Negative B-cell Acute Lymphoblastic Leukemia
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Anti CD19/CD22 chimeric antigen receptor T cell therapy Shanghai YaKe Biotechnology (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
Most Recent Events
- 19 Jan 2021 New trial record